The Iceland-based generic pharmaceuticals company, Actavis, announced last week that it has entered into a binding letter of intent with QRxPharma to launch MoxDuo® IR
eNewsWire UK – International News and PR
The Iceland-based generic pharmaceuticals company, Actavis, announced last week that it has entered into a binding letter of intent with QRxPharma to launch MoxDuo® IR